GlassScriptPhysician profile
Brandon Allen
NPI 1073091963
$3,518.59
in general payments reported to CMS, 2019-2025
23 companies · $1,541 in 2025
The $1,541 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $313 · 2022: $277 · 2023: $433 · 2024: $955 · 2025: $1,541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,928.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $834.93 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $608.75 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $457.43 | 2021-2025 | Ozempic, Wegovy |
| Axsome Therapeutics, INC. | $239.90 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $186.79 | 2022-2025 | Qelbree |
| Alkermes, INC. | $147.49 | 2022-2023 | Aristada, Lybalvi |
| Amgen INC. | $125.00 | 2025 | Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2025 | Caplyta |
| Inspire Medical Systems, INC. | $125.00 | 2024 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.00 | 2025 | Relistor |
| Glaxosmithkline, LLC. | $99.38 | 2024 | Arexvy |
| E.R. Squibb & Sons, L.L.C. | $98.10 | 2024 | Camzyos |
| Gilead Sciences, INC. | $96.75 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $64.28 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $47.95 | 2022-2023 | Abilify Maintena |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $22.76 | 2023 | Ingrezza |
| Biohaven Pharmaceutical Holding Company LTD. | $18.99 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.30 | 2023 | Quviviq |
| Lundbeck LLC | $18.21 | 2023 | Abilify Maintena |
| Genentech USA, INC. | $15.92 | 2021 | |
| Lilly USA, LLC | $14.90 | 2025 | Zepbound |
| Ironshore Pharmaceuticals INC. | $14.08 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.68 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.